Background-Primary aldosteronism (PA) is a common and underdiagnosed disease with significant morbidity potentially cured by surgery. We aim to assess if the long-term cardiovascular benefits of identifying and treating surgically correctable PA outweigh the upfront increased costs in patients at the time patients are diagnosed with resistant hypertension (RH). Methods and Results-A decision-analytic model compares aggregate costs and systolic blood pressure changes of 6 recommended or implemented diagnostic strategies for PA in a simulated population of at-risk RH patients. We also evaluate a 7th "treat all" strategy wherein all patients with RH are treated with a mineralocorticoid-receptor antagonist without further testing at RH diagnosis. Changes in systolic blood pressure are subsequently converted into gains in quality-adjusted life years (QALYs) by applying National Health and Nutrition Examination Survey data on concomitant risk factors to an existing cardiovascular disease simulation model. QALYs and lifetime costs were then used to calculate incremental cost-effectiveness ratios for the competing strategies. The incremental cost-effectiveness ratio for the strategy of computerized tomography (CT) followed by adrenal venous sampling (AVS) was $82 000/QALY compared with treat all. Incremental cost-effectiveness ratios for CT alone and AVS alone were $200 000/QALY and $492 000/QALY; the other strategies were more costly and less effective. Integrating differential patient-reported health-related quality of life adjustments for patients with PA, and incremental cost-effectiveness ratios for screening patients with CT followed by AVS, CT alone, and AVS alone were $52 000/QALY, $114 000/QALY, and $269 000/QALY gained. Conclusions-CT scanning followed by AVS was a cost-effective strategy to screen for PA among patients with RH.
H ypertension ( Table I in the Data Supplement) affects 76 million Americans and is the leading cause of heart disease, stroke, and death. 1 Prevalence of resistant hypertension (RH) is estimated between 12% and 30% of the hypertensive population. [2] [3] [4] The Joint National Committee suggests referral to a hypertension specialist in this subset of patients, although practice recommendations for the screening and diagnosis of secondary causes of hypertension vary. 2, 5, 6 Primary aldosteronism (PA) is the most common cause of secondary hypertension and is characterized by autonomous, inappropriately elevated plasma aldosterone, stemming from an aldosterone producing adenoma (APA) or bilateral adrenal hyperplasia (BAH). Because hypertension-frequently the only sign of PA-is so common, the diagnosis of PA is often overlooked. 5 The prevalence of PA in the hypertensive population is estimated to be 10% in recent studies, with nearly half being unilateral (ie, surgically correctable) disease. 5, 7, 8 Patients with PA make up 17% to 23% of patients with RH and have worse outcomes. [9] [10] [11] [12] In comparison with primary hypertensive patients matched for blood pressure, patients with both subtypes of PA have 4 times the risk of stroke, 7 times the risk of nonfatal heart attack, and 7 to 12 times the risk of atrial fibrillation. 11, 13 Moreover, patients with PA have worse psychosocial and quality of life scores when compared with matched patients with primary hypertension. [14] [15] [16] Adrenalectomy for APA (ie, unilateral PA) is effective and is shown to reverse cardiovascular and renal complications. 13, [17] [18] [19] However, there are costs and different levels of efficiency associated with the various screening strategies used to determine who is most likely to benefit from surgical November 2015 intervention. Furthermore, even small changes in blood pressure have been shown to have significant downstream effects on cardiovascular events. 20, 21 Treatment with mineralocorticoid-receptor antagonists (MRAs) also yields significant improvements in blood pressure and regression of left ventricular hypertrophy in all PA subtypes. 13, 17, 19, 22 We hypothesize that it is cost-effective to screen the resistant hypertensive population for PA, which is known to have a high proportion of patients with PA. Specifically, we postulate that the improvements in blood pressure and consequent reductions in downstream cardiovascular events, in addition to improvements in quality of life resulting from appropriate treatment of patients with PA, outweigh the upfront cost to establishing a PA diagnosis and initiating disease-specific medical treatment or surgery when appropriate. In this analysis, we use a decision-analytic approach to compare recommended strategies and strategies commonly used in practice for PA screening and identification of patients with surgically correctable disease in the RH population versus treating all patients with MRAs.
Methods

Model Structure
A decision-analytic model ( Figure 1 ) was used to compare the aggregate intervention costs and effectiveness associated with 6 screening strategies that are both diagnostic (ie, to distinguish primary hyperaldosteronism from primary hypertension) and help with lateralization (ie, to distinguish surgically correctable APA from BAH in those with positive blood tests) in a simulated cohort of patients with RH. As a clearly superior strategy has not been proven, we chose to perform a comprehensive analysis including many recommended strategies and commonly used algorithms in practice.
We considered 6 screening strategies (Table 1) to identify those patients with unilateral, surgically correctable hyperaldosteronism (ie, APA). All of these strategies begin with an aldosterone to renin ratio (ARR); patients with a negative ARR are started on a MRA. After a positive ARR, patients received one of the following testing options: (1) Confirmatory saline-infusion test (SIT), abdominal computerized tomography (CT), and adrenal venous sampling (AVS) (strategy SIT/ CT/AVS), (2) CT and AVS (CT/AVS), (3) SIT and AVS (SIT/AVS), (4) AVS only, (5) SIT and CT (SIT/CT), or (6) CT only. A seventh strategy included upfront treatment with an MRA in all RH patients without further testing. Spironolactone was chosen as the base-case MRA as it is the least costly yet still effective medication against which to compare potential surgical strategies. We aimed to assess the consequences of immediate action at RH diagnosis as it has been shown that length of time with PA is correlated with failure of cure. Therefore, a strategy of medical trial followed by surgery was not considered.
On the bascis of the best available published evidence ( Table 2  and Table II in the Data Supplement), we assumed that patients with surgically treated APA would obtain an additional 10 mm Hg reduction in systolic blood pressure (SBP) compared with PA patients treated with MRA. In strategy MRA only, all patients with RH were treated upfront with MRA without ARR screening as it has been shown that primary hypertensive patients also respond, albeit to a lesser extent, to MRA therapy. 22, 23 All patients in all other strategies who had a negative ARR, negative CT (ie, no nodules found in either adrenal), or who underwent unsuccessful surgery (ie, those with BAH or primary hypertension undergoing surgery) were given MRA therapy with resultant decreases in blood pressure at varying levels predicted by the true underlying RH cause (ie, patients with primary hypertension would have a reduction in SBP of 10 mm Hg, and those with PA would have a reduction of 20 mm Hg).
For the intervention decision tree, the clinical starting point was a patient with RH. For the primary analysis, we made several important assumptions: (1) patients were all considered surgical candidates; (2) patients diagnosed with unilateral PA (appropriately or inappropriately) all underwent laparoscopic adrenalectomy; (3) false-positive rates (ie, falsely determined to be PA) of CT results for RH patients with primary hypertension were reflective of prevalence of incidental adrenal nodules in the population 24, 25 ; (4) if abdominal CT indicated an abnormality on both sides, patients either proceeded to AVS and surgery if AVS lateralized to 1 adrenal gland (strategies SIT/CT/AVS and CT/AVS), or in CT-only strategies (strategies SIT/CT and CT only) patients were treated with MRA; and (5) if CT did not show abnormalities in either adrenal gland, in CT only strategies (strategies SIT/CT and CT only) patients were treated with MRA.
TreeAge Pro 2014 (TreeAge Software, Williamstown, MA) was used to construct and analyze the intervention model. The change in SBP, change in the number of antihypertensive medications after treatment (estimates obtained from the literature), and differential projected annual costs of antihypertensive regimens were calculated for each strategy in the immediate intervention model.
Costs
The analysis was performed from a healthcare system perspective. Best available cost and probability estimates were extracted from the literature ( Table 2 and Table II in the Data Supplement). The costs of screening, surgery, complications, and medications were included in the analysis, but nonhealthcare-related costs to the patient were not.
Quality-Adjusted Life Years and Lifetime Costs
Changes in SBP and cost of antihypertensive medications per strategy from the decision tree model were subsequently converted into gains in quality-adjusted life years (QALYs) and changes in lifetime cardiovascular disease (CVD) costs using a previously developed and validated CVD model, which is able to evaluate the long-term cardiovascular, costs, events ,and mortality for each change in blood pressure reduction. 26 The reductions in blood pressure and costs associated with each intervention strategy were applied to a National Health and Nutrition Examination Survey (NHANES) population with additional risk factor data to project CVD events.
From 40 790 patients available in the continuous NHANES database from 2005 to 2012, a cohort of 836 patients was selected according to the following criteria: (1) patients with SBP ≥160 mm Hg (presumed RH) and (2) patients with available data on cardiovascular risk factors required to assess 10-year Framingham risk score. 20 These patients were sampled with replacement to create the simulation
WHAT IS KNOWN
• Primary hyperaldosteronism is the most common cause of secondary hypertension and makes up ≈20% of the resistant hypertensive population. • Patients with primary hyperaldosteronism have worse cardiovascular outcomes compared with matched patients with primary hypertension. • Adrenalectomy is an effective treatment for primary hyperaldosteronism in ≈50% of patients.
WHAT THE STUDY ADDS
• At an accepted willingness-to-pay threshold, screening for primary hyperaldosteronism in the resistant hypertensive population is cost-effective in comparison with medical treatment alone. • Computerized tomography followed by confirmatory adrenal venous sampling is the optimal screening strategy for identifying patients with surgically correctable (ie, unilateral) adrenal disease. cohort (1 000 000 patients) and entered into the CVD Markov model ( Figure I in the Data Supplement) with microsimulation to assess comparative discounted lifetime costs and QALYs (ie, incremental cost-effectiveness ratios, ICERs). 26 Briefly, each year, patients had a probability of developing CVD (ie, coronary heart disease, stroke, or CVD-related death) based on Framingham risk function and a probability of death from other causes based on age and sex-based life tables ( Table III in the Data Supplement). Differential annual costs of antihypertensive regimens for the years after the initial intervention were calculated for each strategy and factored into the CVD model (details are available in Methods section and Table II in the Data Supplement).
In the base case analysis, we consider only CVD effects on healthrelated quality-of-life (HRQoL). Utility weights for baseline primary hypertensive patients and downstream health states within the CVD model were based on a broad national sample of community-based, patient-reported EQ-5D utility scores associated with chronic diseases. 27 We also performed an alternative analysis that incorporated a possible utility reduction owing to untreated PA. Prior data suggest that patients with PA have worse quality of life scores when compared with patients with primary hypertension. [14] [15] [16] We derived estimates of utility weights (ie, measure of HRQoL) from longitudinal survey data using the Short Form-12v1 in a cohort of patients before and after treatment with adrenalectomy or MRA. Data were catalogued and translated into interval scale utilities (0 = dead to 1 = perfect health) using the QualityMetric health state score system, SF6D, for integration of a change of utility into the CVD model. The study was approved by the institutional review board and subjects gave informed consent. For the purposes of this study, median differences after treatment between surgical after medically treated PA patients were used to adjust the base utility for each intervention strategy for the CVD model.
QALYs and lifetime CVD costs from the simulation model and per-patient diagnostic and treatment costs from the decision tree model were then used to calculate ICERs (cost per QALY) for the 7 competing strategies. Future costs and QALYs were discounted at 3% per annum. 28 A willingness-to-pay (WTP) threshold of $US 150 000/QALY gained was used as a benchmark for cost-effectiveness, following the American College of Cardiology/American Heart Association position paper on integration of cost-effective data into clinical practice. 29
Sensitivity Analysis
We performed univariate sensitivity analyses on all variables to assess effects of varying key model parameters on our results ( Table 2 and Figures II-VI in the Data Supplement). Given recommendations for utilization of CT for surgical planning and to assess for potential malignancy, 6, 30 we also tested the additional cost of the CT (with all patients still undergoing AVS regardless of the CT results) in the AVS-only strategies (SIT/AVS and AVS only). Probabilistic sensitivity analysis was performed to assess the effects of parameter estimate uncertainty.
Results
Costs and outcomes by strategy are shown in Table 3 . Of the strategies evaluated, proceeding directly to AVS only yielded the greatest SBP reduction (12.49 mm Hg) and cost. Treating all patients with MRA was the least costly-given no further testing or surgery-but with the lowest SBP reduction. Using preliminary patient-reported survey data to measure the effects of treatment on HRQoL in patients with PA, we found a greater improvement with surgery when compared with MRA. A median utility decrement of 0.054 (IQR, 0-0.079) was found for those with PA treated medically versus surgically. Moreover, the strategies that resulted in more patients with true surgically correctable PA being treated with surgery also had a greater increase in quality of life (ie, AVS only strategy). The 836 patients from the NHANES database had a mean age of 67.6 years, were 58.0% female, and had an initial mean SBP of 175 mm Hg. After entering intervention costs and changes in SBP into the CVD model, we found that none of the strategies with confirmatory SIT were cost-effective (ie, all were dominated). CT/AVS, CT only, and AVS only strategies all resulted in gains in life expectancy compared with treating all patients with MRA (ie, on the efficiency frontier) at an increased cost. At US WTP threshold of $150 000/QALY and without adjustments in HRQoL for patients with surgically untreated PA, CT/AVS strategy is the cost-effective choice with an ICER of $82 000/QALY (Figure 2 ). After integrating conservative HRQoL reductions for PA patients treated with MRAs alone, CT only strategy (with an ICER of $114 000/ QALY) would be the cost-effective choice at this WTP threshold ( Figure 3) .
The proportion of patients undergoing surgery by underlying disease is shown in Table IV in the Data Supplement. Using the CT/AVS strategy, the preferred strategy at the WTP threshold of $150 000/QALY, 50% of patients with true unilateral PA are treated appropriately with adrenalectomy with a surgical mortality of <0.1%. At the same time, potentially ineffective surgery would occur in 0.1% of patients (ie, patients with BAH or primary hypertension). Surgical mortality in BAH and primary hypertension patients undergoing surgery nears zero.
Sensitivity Analysis
The same 4 strategies remain on the efficiency frontier over a wide-range of sensitivity analyses (Table 2) , specifically through a wide range of prevalence of PA in the RH population ( Figure II in the Data Supplement), prevalence of adrenal incidentalomas, and testing characteristics of screening ARR (Figures III and IV in the Data Supplement). When the prevalence of unilateral PA (APA) increased above 50%, strategy CT/AVS fell off the efficiency frontier. There was no effect on results for sensitivity of screening ARR and confirmatory testing. When the sensitivity and specificity of CT or AVS were diminished or costs of the tests changed significantly, competing strategies became more desirable. However, within reported ranges, our results were consistent. The efficiency frontier remained the same with the additional cost of the CT for surgical planning. Some patients require higher doses of MRA to attain improvement in blood pressure. No significant changes in the efficiency frontier were seen with increasing the cost of this medication ( Figure V in the Data Supplement).
Efficient strategies are dependent on treatment effect, with the key parameters being the SBP change with MRA in patients with PA, and the incremental effect of surgery versus MRA in patients with PA, illustrated in Figure 4 . However, even with a small incremental SBP effect between PA patients treated with surgery and medication, screening strategies to identify appropriate patients for surgery remained on the efficiency frontier ( Figure 5 ). In the base-case analysis, with a 6 mm Hg change in SBP with surgery over MRA, CT/AVS is cost-effective. With including utility adjustments for untreated PA, at a 2 mm Hg improvement, CT/AVS is cost-effective. In most reports, the average age at diagnosis is younger in patients with PA than with primary hypertension. Although patients entering the model did not have a diagnosis of PA as the cause of RH (by design), we tested our hypothesis that screening for PA at a younger age may increase the benefit of screening by performing a subgroup analysis in patients <50 years old from our NHANES cohort. We found the same strategies were cost-effective with substantial improvements in the ICERs (Figure 6 ). Very few patients with RH are younger than 40 years old (average age in our cohort was 67), and therefore, we chose not to test stratifying patients for surgery following a unilateral CT findings by age as recommended by the Endocrine Practice guidelines. 6 Finally, to test our assumption that NHANES patients in our sample had RH (versus inadequate treatment or poor patient adherence to antihypertensive regimen), we performed a subgroup analysis on patients who confirmed having a current prescription of antihypertensive medications on the NHANES questionnaire ( Figure VI in the Data Supplement). We found that the same strategies were cost-effective in this subgroup analysis.
The results of the probabilistic sensitivity analysis are shown as a cost-effectiveness acceptability curve (Figure 7) . This graph shows the proportion of the random samplings of parameter distributions resulting in the greatest net health benefit (vertical axis) at increasing WTP thresholds (horizontal axis). At a WTP threshold of $150 000/QALY, a strategy involving screening and subtype diagnosis of PA was costeffective in 87% of simulations.
Discussion
Based on this analysis, our results support our hypothesis that screening for PA and surgically treating those with appropriate indications in all patients with RH (versus the MRA only strategy) are cost-effective. This result was consistent in the base-case and exhaustive sensitivity analyses. Which of the remaining intervention strategies is preferred depends on the WTP threshold. Before integrating the effects of untreated PA on health-related quality of life, the intervention strategy CT/ AVS was the only cost-effective management strategy with an ICER of $82 000/life year saved. Although it may be counterintuitive that CT/AVS would be more cost-effective than CT alone, this can be explained by the costs incurred from downstream medical and CVD-event related costs from removing the wrong adrenal gland (ie, false-positive CT) and failing to remove a functional adenoma in cases with bilateral CT abnormalities in the CT-only strategy. This highlights the value of AVS in helping to lateralize lesions preoperatively. Finally, our study found that the differential effect of treatment on SBP (ie, medical versus surgical in patients with PA) had the greatest impact on the ICERs. A definitive controlled trial directly comparing the impact of medical management with surgery would be needed to clarify the magnitude of benefit that would be expected with adrenalectomy relative to treatment with MRA. Despite this variation, we found that with only small incremental differences in SBP in patients with PA undergoing surgery versus medical therapy (ie, 6 mm Hg in the base case and 2 mm Hg when additional quality of life decrements for those with PA were taken into account), screening for surgically correctable PA was cost-effective, as small changes in blood pressure have been shown to have significant downstream effects on cardiovascular events. 20, 21 When a modest reduction in utility associated with untreated PA was incorporated into the model, there were notable decreases in the ICERs for all screening strategies. At a threshold of $150 000/QALY, CT only becomes the preferred strategy, with an ICER of $114 000/QALY. We postulate that an early improvement in quality of life may be derived from several factors including taking fewer medications and associated side-effects, decreased financial burden and fewer office visits. Downstream effects of health-related quality of life may be attributable to lower blood pressure resulting in fewer interventions and cardiovascular events. Psychometric survey data show that patients with PA have increased anxiety, depression, and SF36 domains compared with the general population and primary hypertensive controls. 14, 16 Studies suggest that patients show greater improvements after adrenalectomy compared with MRA at 6 months post treatment. 16 In addition, patients can experience debilitating side effects from MRAs including gynecomastia and impotence. Although we do not currently have data on the differential effects of spironolactone versus eplerenone on HRQoL, we expect the potential improvement in HRQoL from fewer medication side effects to be offset by the incremental cost of eplerenone.
Our results show that the strategy with AVS alone after positive screening ARR resulted in the greatest reductions in SBP in the intervention model and greatest quality-adjusted life expectancy; however, this came at significant cost, leading to a high ICER. Use of AVS in all patients screening positive for PA is controversial. Proponents cite the need for AVS given the high false-negative and false-positive rates of CT for small aldosterone-secreting adrenal adenomas, whereas opponents cite technical difficulty, cost, and risk of adverse effects. [31] [32] [33] [34] [35] [36] The generalizability of published reports on the performance of AVS in tertiary care centers is open to question, given the lower success rates seen in the few published reports from nonacademic centers. 30, 32 Moreover, strategies with AVS remained on the efficiency frontier over a wide range of reported success rates of AVS. The addition of a CT for presurgical planning-commonly practiced-only adds a small incremental cost to this strategy and does not alter the effectiveness. Lastly, it is important to remember that although WTP thresholds are commonplace in Europe, they are contentious in the United States; values vary depending on the economy, location, relevant decision maker, values of the population, and the resources available. 37 Estimated on current medical care spending in the United States, a range of $183 000/QALY to $264 000/QALY may be considered more reflective of current WTP. 38 Moreover, although guidelines recommend the use of confirmatory testing, we did not find any strategy that included SIT to be cost-effective. This is likely because of the fact the ARR as a screening test is fairly accurate and that the small incremental benefit from confirmatory testing does not outweigh the cost. It should be noted that we did not include the costs of SIT implementation (ie, 2 hours of staff observation for infusion) nor potential morbidity associated with changing or withholding hypertensive regimens or of salt-loading in this analysis. Inclusion of these additional costs would make strategies that include confirmatory testing even less cost-effective.
Our study has limitations, common to decision-analytic methods, which arise when using simplifying assumptions to model complex disease care pathways. First, we made the presumption that patients above a SBP threshold in the NHANES database had RH and not untreated hypertension. If our assumption was incorrect, then this would translate into a lower percentage of truly resistant patients and, therefore, a decreased proportion of patients with PA. We would expect that in a pure RH population our screening strategies would be even more cost-effective. 16, 22, 39 Indeed, our subgroup analysis of NHANES patients self-reporting use of antihypertensives resulted in the same cost-effective strategies ( Figure VI in the Data Supplement). Second, many retrospective studies may have misclassified patients at diagnosis by not properly identifying subtype (ie, by not performing AVS) or by leaving open to possibility that failure of adrenalectomy was from underlying primary hypertension (ie, because no postoperative ARR was performed). We expect that the majority of the misclassification is in failed identification of appropriate surgical candidates who would benefit most from diagnosis and treatment. For example, being younger or female is positively associated with hypertension cure after surgery for APA, but these patient characteristics were not taken under account in the base-case analysis. [40] [41] [42] Furthermore, given that patients with BAH do not undergo surgery, it is impossible to confirm the diagnosis of these patients, making specificity of tests challenging to determine. Finally, although medical and surgical treatment have been shown to have positive treatment effects, there are limited data on the comparative effect of treatment on blood pressure between the following 3 groups in controlled trials: (1) patients with primary hypertension receiving MRAs, (2) patients with PA receiving MRAs, and (3) patients with PA undergoing adrenalectomy. Rossi et al 13 showed comparable efficacy of surgery and MRAs in lowering blood pressure in patients with PA. Other reports cite greater improvement in blood pressure between patients undergoing surgery compared with MRAs in patients with PA (Table II in the Data  Supplement) . However, more efficacy data are needed to strengthen the conclusions of this study. In a cost analysis of patients with PA (without comparison to MRA alone), Reimel et al 43 found surgery to be significantly less expensive over a lifetime. It is important to note that while the incremental increased in life expectancy between strategies may be interpreted as small, it should be emphasized that this is an average result over a million simulated patients. Therefore, although many patients in this population (ie, 80% of whom have primary hypertension) have only a minimum benefit with these strategies, there is a smaller but substantial subset of patients (≈10% of the RH population with APA) who gain substantial health benefits.
Although we did include NHANES patients with a prior CVD event in this study, we chose not to enhance the relative risk of prior CVD events in the PA subpopulation. In a crosssectional study, Milliez et al 11 found that compared with matched controls, patients with PA were significantly more likely to have had a previous stroke or myocardial infarction. Catena et al 10 confirmed the findings of higher pretreatment risk of CVD events and attenuation of this differential effect with treatment. We chose not to incorporate this into the model to isolate the benefit of screening and subsequent comparative improvement in SBP on outcomes. Our findings would be strengthened by integrating this differential history of CVD events given the significantly worse long-term outcomes in those with a prior CVD event. In practice, there is frequently a delay in diagnosing PA. Given that time with PA correlates with more CVD events and with failure of cure from surgery, early diagnosis of patients with PA-and in particular those with surgically correctable disease-is essential. Integration of this a priori differential risk of CVD between patients with PA and patients with primary hypertension is an important area for investigation.
In conclusion, our study addresses an increasingly important public health concern. Primary hyperaldosteronism is a common disease that is currently, grossly underdiagnosed and treated. Given a conservative estimate that 12.5% of the hypertensive population has RH, 20% of RH patients have PA, and half of patients with PA have unilateral disease, we estimate that 1 million hypertensive patients in the United States could be cured with surgery. 9, 12, 44 At accepted WTP thresholds in the test, our results suggest that CT followed by AVS is a cost-effective strategy to screen for PA among patients with RH. Given that CVD events are more likely and that HRQoL is significantly worse in untreated patients with PA, and given that there is a reversal of this increased risk with treatment, identifying and appropriately treating patients with RH could have significant impact.
